In particular, PRS may help differentiate BC risk among carriers of PVs in well-established moderate-penetrance genes, such as CHEK2 and ATM, enabling more informed decisions about screening practices and more personalized risk management approaches [175]. This evidence concerns the gene ATM and breast cancer.